See more : Microcosm Technology Co., Ltd. (3354.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of ViewRay, Inc. (VRAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ViewRay, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Dexter Studios Co.,Ltd. (206560.KQ) Income Statement Analysis – Financial Results
- Aimflex Berhad (0209.KL) Income Statement Analysis – Financial Results
- C.P. Pokphand Co. Ltd. (0043.HK) Income Statement Analysis – Financial Results
- CooTek (Cayman) Inc. (CTKYY) Income Statement Analysis – Financial Results
- IMRIS Inc. (IMRSQ) Income Statement Analysis – Financial Results
ViewRay, Inc. (VRAY)
About ViewRay, Inc.
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.21M | 70.12M | 57.02M | 87.78M | 80.96M | 34.04M | 22.24M | 10.39M | 0.00 | 3.16M |
| Cost of Revenue | 92.16M | 69.78M | 61.08M | 93.26M | 74.36M | 27.71M | 25.87M | 14.54M | 0.00 | 8.19M |
| Gross Profit | 10.05M | 335.00K | -4.06M | -5.48M | 6.60M | 6.33M | -3.63M | -4.15M | 0.00 | -5.03M |
| Gross Profit Ratio | 9.83% | 0.48% | -7.12% | -6.24% | 8.16% | 18.60% | -16.32% | -39.98% | 0.00% | -159.16% |
| Research & Development | 32.43M | 31.85M | 25.01M | 23.79M | 16.52M | 14.71M | 11.44M | 10.45M | 0.00 | 8.78M |
| General & Administrative | 52.44M | 56.09M | 61.73M | 65.72M | 50.11M | 31.38M | 23.50M | 21.69M | 0.00 | 9.51M |
| Selling & Marketing | 30.49M | 16.04M | 15.18M | 25.81M | 15.06M | 8.41M | 5.60M | 5.14M | 0.00 | 3.78M |
| SG&A | 82.93M | 72.14M | 76.91M | 91.52M | 65.18M | 39.79M | 29.10M | 26.82M | 0.00 | 13.29M |
| Other Expenses | 3.17M | -2.17M | 585.00K | 3.20M | 6.39M | -16.77M | -512.00K | -117.00K | 0.00 | 0.00 |
| Operating Expenses | 115.36M | 103.98M | 101.92M | 115.32M | 81.70M | 54.50M | 40.55M | 37.27M | 0.00 | 22.07M |
| Cost & Expenses | 207.52M | 173.77M | 162.99M | 208.58M | 156.05M | 82.21M | 66.41M | 51.82M | 0.00 | 30.26M |
| Interest Income | 1.69M | 13.00K | 791.00K | 1.72M | 8.00K | 5.00K | 2.00K | 2.00K | 0.00 | 4.00K |
| Interest Expense | 5.06M | 4.24M | 3.31M | 4.33M | 7.70M | 7.25M | 5.95M | 3.45M | 0.00 | 97.00K |
| Depreciation & Amortization | 4.85M | -2.16M | 1.38M | 4.92M | 3.50M | 2.20M | 1.71M | 1.26M | 0.00 | 1.15M |
| EBITDA | -100.46M | -105.81M | -104.60M | -115.87M | -68.70M | -62.73M | -44.69M | -41.54M | 0.00 | -26.04M |
| EBITDA Ratio | -98.29% | -150.90% | -183.46% | -132.00% | -84.85% | -184.28% | -200.95% | -399.83% | 0.00% | -824.34% |
| Operating Income | -107.13M | -103.65M | -105.98M | -120.80M | -75.09M | -48.16M | -44.18M | -41.43M | 0.00 | -27.10M |
| Operating Income Ratio | -104.81% | -147.82% | -185.87% | -137.61% | -92.75% | -141.48% | -198.66% | -398.72% | 0.00% | -857.77% |
| Total Other Income/Expenses | -203.00K | -6.40M | -1.93M | 596.00K | -1.30M | -24.01M | -6.46M | -3.57M | 0.00 | -125.00K |
| Income Before Tax | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M | -72.18M | -50.64M | -44.99M | 0.00 | -27.22M |
| Income Before Tax Ratio | -105.01% | -156.94% | -189.26% | -136.93% | -94.36% | -212.02% | -227.71% | -433.05% | 0.00% | -861.73% |
| Income Tax Expense | 203.00K | -3.91M | -2.53M | 2.87M | 1.30M | -9.52M | 3.73M | 1.00K | 0.00 | 0.00 |
| Net Income | -107.53M | -106.13M | -105.38M | -123.07M | -76.40M | -72.18M | -50.64M | -45.00M | 0.00 | -27.22M |
| Net Income Ratio | -105.21% | -151.36% | -184.82% | -140.20% | -94.36% | -212.02% | -227.71% | -433.06% | 0.00% | -861.73% |
| EPS | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| EPS Diluted | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| Weighted Avg Shares Out | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
| Weighted Avg Shares Out (Dil) | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
Helsinki University Hospital Selects MRIdian® System for Installation at Comprehensive Cancer Center
CLEVELAND, Oct. 25, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Helsinki University Hospital has purchased a MRIdian® System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital. The Comprehensive Cancer Center is...
Baptist Health South Florida to Acquire a Second ViewRay MRIdian® MR-Guided Radiation Therapy System
CLEVELAND, Oct. 22, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Baptist Health South Florida will acquire a second MRIdian MR-guided radiation therapy system, joining other leading institutions from around the globe investing in multiple MRIdian systems. Baptist Health is expanding its...
ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on October 28, 2021
CLEVELAND, Oct. 18, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Thursday, October 28, 2021. The event will begin at 8:30 am ET /...
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations
CLEVELAND, Sept. 29, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.
ViewRay® to Partcipate in the Cantor Global Healthcare Conference
CLEVELAND, Sept. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the Cantor Global Healthcare Conference.
ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CLEVELAND, Aug. 27, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will...
Amsterdam University Medical Centers establishes same-day ablative treatment service using MRIdian® to Streamline the Patient Experience.
CLEVELAND, Aug. 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has started offering "same-day ablative treatment" using MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) for patients who are eligible...
UCLA Health Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
CLEVELAND, Aug. 17, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that UCLA Health joins the Siteman Cancer Center at Washington University, Seoul National University Hospital and Amsterdam UMC in surpassing the treatment of 1,000 patients using the MRIdian®...
ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2021 Results - Earnings Call Transcript
ViewRay, Inc. (VRAY) CEO Scott Drake on Q2 2021 Results - Earnings Call Transcript
Why ViewRay Stock Is Sinking Today
Investors didn't like the company's Q2 update.
Source: https://incomestatements.info
Category: Stock Reports